Leaflet IMPAVIDO 50mg capsules

Product code:
W69190001
Quantity:
56
Indicated for:
leishmaniasis
Route of administration:
oral
Substance:
miltefosine (antiprotozoal)
ATC
P01CX04 — Antiparasitic products, insecticides and repellents | Agents against leishmaniasis and trypanosomiasis | Other agents against leishmaniasis and trypanosomiasis
Miltefosine is an antiprotozoal agent used for the treatment of visceral and cutaneous leishmaniasis. It works by disrupting the cell membranes of the parasite, leading to its death.

The medication is taken orally, usually once or twice daily, with the duration of treatment varying based on the type and severity of the infection. Common side effects include nausea, vomiting, diarrhea, and abdominal pain.

Miltefosine is contraindicated in pregnant and breastfeeding women, as well as in patients with hypersensitivity to the active substance. Its use also requires careful monitoring to prevent renal and hepatic toxicity.

This medication is an important option for the treatment of leishmaniasis, helping to reduce mortality and alleviate symptoms.

General data about IMPAVIDO 50mg

Substance:
miltefosine
Date of latest medicines list:
01-03-2026
Product code:
W69190001
Concentration:
50mg
Pharmaceutical form:
capsules
Quantity:
56
Product type:
Generic medicine
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
PAESEL + LOREI GMBH & CO. KG - GERMANIA
Holder:
CN UNIFARM S.A. - ROMANIA
Number:
748/2022/01
Shelf life:
5 years

Pharmaceutical forms available for miltefosine

Concentrations available for miltefosine

  • 50mg
  • 60mg/ml